Tags

Type your tag names separated by a space and hit enter

[Efficacy and safety of olmesartan medoxomil versus losartan potassium in Chinese patients with mild to moderate essential hypertension].
Zhonghua Xin Xue Guan Bing Za Zhi. 2006 Oct; 34(10):877-81.ZX

Abstract

OBJECTIVE

To evaluate the efficacy and safety of olmesartan medoxomil compared with losartan potassium in patients with mild to moderate essential hypertension.

METHOD

This is a randomized, double-blind, double-dummy, active-controlled, parallel, multi-center study. After a 2-week placebo run-in period, a total of 287 eligible subjects were randomized at 1:1 ratio to receive olmesartan medoxomil 20 mg or losartan potassium 50 mg, once daily for 8 weeks. The blood pressure was assessed after 4 weeks treatment. If the subject's seating diastolic blood pressure (SeDBP) was still >or=90 mm Hg, the dosage was doubled for another 4 weeks; for those subjects whose SeDBP was <90 mm Hg after 4-week treatment, the initial dosage remained unchanged and the treatment continued until completion of the study.

RESULTS

(1) The mean trough reduction in SeDBP from baseline in olmesartan group was significantly greater than that in losartan group after 4 weeks (11.72 mm Hg vs 9.23 mm Hg, P=0.004) and 8 weeks treatment (12.94 mm Hg vs 11.01 mm Hg, P=0.035). (2) The number and percentage of responders in olmesartan group (81, 65.3%) were statistically higher than those (68, 52.7%) in losartan group (P=0.028) after 4 weeks treatment and were similar between the two groups after 8 weeks treatment (P>0.05). (3) Individual and overall trough/peak ratios of DBP and SBP in 24-hour ambulatory blood pressure monitoring were higher in olmesartan group than losartan group. The hypotensive effect of olmesartan was more durable than losartan at 24 hour interval. (4) The incidence of study drug-related adverse events (AEs) in olmesartan group (10.5%) was similar as that in losartan group (13.9%, P>0.05). Most of these AEs were mild and transient.

CONCLUSION

This study shows that olmesartan medoxomil, at oral dose of 20 mg-40 mg once daily was effective and safe for hypertension treatment and the hypotensive effect was superior to losartan potassium (50 mg-100 mg once daily).

Authors+Show Affiliations

Department of Cardiology, Zhong Shan Hospital, Fudan University, Shanghai 200032, China. jrzhu@zshospital.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

chi

PubMed ID

17217710

Citation

Zhu, Jun-ren, et al. "[Efficacy and Safety of Olmesartan Medoxomil Versus Losartan Potassium in Chinese Patients With Mild to Moderate Essential Hypertension]." Zhonghua Xin Xue Guan Bing Za Zhi, vol. 34, no. 10, 2006, pp. 877-81.
Zhu JR, Cai NS, Fan WH, et al. [Efficacy and safety of olmesartan medoxomil versus losartan potassium in Chinese patients with mild to moderate essential hypertension]. Zhonghua Xin Xue Guan Bing Za Zhi. 2006;34(10):877-81.
Zhu, J. R., Cai, N. S., Fan, W. H., Zhu, D. L., He, B., Wu, Z. G., Ke, Y. N., Guo, J. X., Ma, H., Huang, J., Li, X. L., & Chen, Y. Z. (2006). [Efficacy and safety of olmesartan medoxomil versus losartan potassium in Chinese patients with mild to moderate essential hypertension]. Zhonghua Xin Xue Guan Bing Za Zhi, 34(10), 877-81.
Zhu JR, et al. [Efficacy and Safety of Olmesartan Medoxomil Versus Losartan Potassium in Chinese Patients With Mild to Moderate Essential Hypertension]. Zhonghua Xin Xue Guan Bing Za Zhi. 2006;34(10):877-81. PubMed PMID: 17217710.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Efficacy and safety of olmesartan medoxomil versus losartan potassium in Chinese patients with mild to moderate essential hypertension]. AU - Zhu,Jun-ren, AU - Cai,Nai-sheng, AU - Fan,Wei-hu, AU - Zhu,Ding-liang, AU - He,Ben, AU - Wu,Zong-gui, AU - Ke,Yuan-nan, AU - Guo,Jing-xuan, AU - Ma,Hong, AU - Huang,Jun, AU - Li,Xin-li, AU - Chen,Yun-zhen, PY - 2007/1/16/pubmed PY - 2007/10/17/medline PY - 2007/1/16/entrez SP - 877 EP - 81 JF - Zhonghua xin xue guan bing za zhi JO - Zhonghua Xin Xue Guan Bing Za Zhi VL - 34 IS - 10 N2 - OBJECTIVE: To evaluate the efficacy and safety of olmesartan medoxomil compared with losartan potassium in patients with mild to moderate essential hypertension. METHOD: This is a randomized, double-blind, double-dummy, active-controlled, parallel, multi-center study. After a 2-week placebo run-in period, a total of 287 eligible subjects were randomized at 1:1 ratio to receive olmesartan medoxomil 20 mg or losartan potassium 50 mg, once daily for 8 weeks. The blood pressure was assessed after 4 weeks treatment. If the subject's seating diastolic blood pressure (SeDBP) was still >or=90 mm Hg, the dosage was doubled for another 4 weeks; for those subjects whose SeDBP was <90 mm Hg after 4-week treatment, the initial dosage remained unchanged and the treatment continued until completion of the study. RESULTS: (1) The mean trough reduction in SeDBP from baseline in olmesartan group was significantly greater than that in losartan group after 4 weeks (11.72 mm Hg vs 9.23 mm Hg, P=0.004) and 8 weeks treatment (12.94 mm Hg vs 11.01 mm Hg, P=0.035). (2) The number and percentage of responders in olmesartan group (81, 65.3%) were statistically higher than those (68, 52.7%) in losartan group (P=0.028) after 4 weeks treatment and were similar between the two groups after 8 weeks treatment (P>0.05). (3) Individual and overall trough/peak ratios of DBP and SBP in 24-hour ambulatory blood pressure monitoring were higher in olmesartan group than losartan group. The hypotensive effect of olmesartan was more durable than losartan at 24 hour interval. (4) The incidence of study drug-related adverse events (AEs) in olmesartan group (10.5%) was similar as that in losartan group (13.9%, P>0.05). Most of these AEs were mild and transient. CONCLUSION: This study shows that olmesartan medoxomil, at oral dose of 20 mg-40 mg once daily was effective and safe for hypertension treatment and the hypotensive effect was superior to losartan potassium (50 mg-100 mg once daily). SN - 0253-3758 UR - https://www.unboundmedicine.com/medline/citation/17217710/[Efficacy_and_safety_of_olmesartan_medoxomil_versus_losartan_potassium_in_Chinese_patients_with_mild_to_moderate_essential_hypertension]_ L2 - http://journal.yiigle.com/LinkIn.do?linkin_type=pubmed&amp;issn=0253-3758&amp;year=2006&amp;vol=34&amp;issue=10&amp;fpage=877 DB - PRIME DP - Unbound Medicine ER -